SUNRISE, Fla., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today it has appointed a five-member Advisory Board comprised of local and international business, financial and marketing executives to assist in the development of the company's new business plan.
In addition, Corporate & Securities attorney David E. Wells, a Shareholder with the law firm of Greenberg Traurig has been engaged by Bioheart as SEC counsel.
"The trusted advice and valued input of this group of change agents will refine Bioheart's short term and long term strategies for raising capital, monetizing assets and developing alternative revenue streams," said Mike Tomas, president and CEO. "We are also very pleased that David Wells and his legal team at Greenberg Traurig will be providing us with the counsel and guidance needed to take Bioheart to the next level."
The members of the Advisory Board have successfully grown companies, held C-level positions at public and privately held companies and executed complex million-dollar financial transactions.
The five-member Advisory Board members consist of:
Bioheart officers and executives on the Advisory Board include Chairman of the Board, William P. Murphy, M.D.; President/CEO Mike Tomas; and Chief Science Officer Kristin Comella.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.
CONTACT: Media Contact: Christina Grate Becker Public Relations Public Relations, Event Planning and Marketing 2506 Ponce de Leon Blvd. Coral Gables, FL 33134 Telephone 305/444-2181 X 224 Email: email@example.com